Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates Fortress Biotech (FBIO) delivered earnings and revenue surprises of -9.09% and 27.56%, respectively, for the quarter ended March 2025. Do…
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates Fortress Biotech (FBIO) delivered earnings and revenue surprises of 67.09% and 12.58%, respectively, for the quarter ended December 2024. Do…
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical…
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an innovative biopharmaceutical company…
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused…
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023…
Fortress Biotech to Participate in 36th Annual ROTH Conference MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused…